ESBATech AG is a Zurich, Switzerland-based biopharmaceutical company focused on advancing its proprietary antibody fragments for therapeutic applications in inflammatory diseases. Antibody fragments are an emerging area of focus within the monoclonal antibody community and they represent a new class of therapeutics. Due to their smaller molecular size, antibody fragments have a number of therapeutic advantages over whole antibodies.
 

 
The primary advantage of human antibody fragments is their ability to penetrate tissues better than whole antibodies. Additional advantages of antibody fragments include their low cost of development and production. This is due to their ability to be manufactured in microbial expression systems.